Epoch 33: Global Biopharma - China and EU

Access to Capital & Innovation Substrate

Welcome to the 50 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,271 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. This week we continue our discussion on innovation sourcing trends with a sharp focus on China and a lighter touch on Europe.  It is easy to zero in on what is happening in the USA as it is by far the biggest biotech market.  However, interesting things are happening globally that are important to monitor.  Many are skeptical of the quality of Chinese innovation, however as we will show today the situation has changed greatly in recent years, and pharma companies are paying handsomely for access to this innovation.  European biotech continues to remain fiscally responsible and a producer of innovation at more reasonable valuations.

If you're not subbed - it's $5 a month, the price of a grande!  The Thursday market updates will remain FREE and under the paid umbrella.  The Sunday Building Biotech Series is intended to be more forward looking. Monday’s equity research will focus on BridgeBio ($BBIO).  This is one we have highlighted in the past, however we come back to it because they will have the full Phase 3 readout on the ATTR program and options pricing is indicating there will be volatility to play.

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Enough shilling for the day, lots to cover this week, let's get started!

GLOBAL BIOTECH CONDITIONS

Today we aim to continue our discussion on recent biopharma innovation sourcing by diving deeper into the global outlook.  As you will see, this exercise will quickly lead us to China as a blossoming center for scientific substrate.  

Since we are taking an ex-US look at the world today, this will also lead us to have a look at Europe. The European biotech ecosystem has always been there, although capital is often a bit harder to come by vs. the states.  Nevertheless, there is also a rich substrate which often comes at a discount compared to the US.